<DOC>
	<DOCNO>NCT01489995</DOCNO>
	<brief_summary>A 5-period crossover study evaluate effect meal type time migalastat HCl pharmacokinetics healthy male female subject . Subjects randomly assign 1 5 treatment sequence receive treatment course 5 weekly period .</brief_summary>
	<brief_title>Migalastat Food Effect Study</brief_title>
	<detailed_description>This Phase 1 , randomize , open-label , 5-period crossover study evaluate effect meal type time migalastat HCl pharmacokinetics healthy male female subject age 18 65 year . A total 20 subject enrol approximately 14 evaluable subject complete dose critical assessment . Subjects randomly assign 1 5 treatment sequence receive treatment course 5 successive weekly period include single dose migalastat HCl 150 mg fast state reference treatment . There least 7-day washout period dose migalastat HCl follow-up visit approximately 7 10 day last dose Period 5 . All subject screen within 28 day admission clinical unit . In period , subject check clinical unit day prior drug administration relevant assessment ensure continue eligibility dose administration . On Day 1 period , subject receive single dose migalastat HCl within 1 follow 5 treatment regimen follow : - 150 mg migalastat HCl fast state ( reference arm ) - 150 mg migalastat HCl simultaneous consumption glucose drink - 150 mg migalastat HCl 1 hour consumption high fat meal - 150 mg migalastat HCl 1 hour consumption light meal - 150 mg migalastat HCl 1 hour consumption light meal Subjects confine clinical unit 24 hour dose serial blood sample collect PK analysis . Safety assess throughout study monitor clinical laboratory test , ECGs , physical examination , vital sign , AEs .</detailed_description>
	<mesh_term>Fabry Disease</mesh_term>
	<mesh_term>1-Deoxynojirimycin</mesh_term>
	<criteria>Male Female age 18 65 year inclusive Healthy , determine study physician Capable give informed consent Positive HIV Hepatitis B and/or C viruses History drug alcohol abuse addiction within 2 year Smoker consume tobacco product Participation clinical trial within 30 day schedule first dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Food effect</keyword>
	<keyword>GR181413A</keyword>
	<keyword>AT1001</keyword>
	<keyword>migalastat hydrochloride</keyword>
	<keyword>Lysosomal storage disorder</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>